Figure 4
Vorinostat and ABT-737 induce synergistic apoptosis in Eμ-myc lymphomas overexpressing Bcl-2 and Bcl-XL. 4242 Eμ-myc/MSCV, Eμ-myc/Bcl-2, Eμ-myc/Bcl-XL, Eμ-myc/Bcl-w, Eμ-myc/Mcl-1, and Eμ-myc/A1 lymphomas were treated with increasing concentrations of vorinostat (0, 0.5, 1.0, or 5.0 μM) in the presence or absence of ABT-737 or ABT-737e. ABT-737 and ABT-737e were used at a concentration of 0.5 μM for Eμ-myc/Bcl-2 and Eμ-myc/Bcl-XL lymphomas, and at 1.0 μM for Eμ-myc/Bcl-w, Eμ-myc/Mcl-1, and Eμ-myc/A1 cells. Cell membrane disruption (left panels) and MOMP (right panels) were assessed by PI and TMRE staining, respectively. Results shown are the mean and SE from at least 3 separate experiments.
